Cambridge Healthtech Institute’s 12th Annual

Predicting Drug Toxicity

Innovative Tools and Strategies for Early Drug Safety Assessments

June 19-20, 2019


Adverse drug events such as cardiotoxicity, hepatotoxicity and other organ toxicities keep surfacing in the clinic and idiosyncratic drug toxicity continues to haunt the drug development process. New screening technologies, in vitro assays, in vivo models and computational tools continue to be developed, but scientists are still unclear on which models to use, how reliable the data is, and how predictive the translation is of results from in vitro to in vivo. Cambridge Healthtech Institute’s annual Predicting Drug Toxicity conference looks at the scientific and technological progress being made to predict drug-induced toxicities and to better translate these findings to the clinic.

INTEGRATING LEAD OPTIMIZATION AND RISK ASSESSMENT STRATEGIES

Safety Differentiation: Emerging Competitive Edge in Drug Development

Laszlo Urban, MD, PhD, Global Head, Preclinical Secondary Pharmacology, Novartis Institutes for Biomedical Research (NIBR)

Correlation vs. Causation: The Dilemma Facing Hepatotoxicity Risk Assessment in Drug Discovery

William Proctor, PhD, DABT, Associate Director and Senior Scientist, Investigative Toxicology, Department of Safety Assessment, Genentech Inc.

NEW MODELS FOR SAFETY SCREENING

Evaluating ADC Related Peripheral Neuropathy with Advanced In Vitro Models

Terry Van Vleet, PhD, DABT, Head of Molecular and Computational Toxicology, Department of Preclinical Safety, Abbvie  

In vitro Models and Assays to Predict Drug-induced Kidney Toxicity During Drug Discovery

Anna-Karin Sjögren, PhD, Drug Safety Scientist, Drug Safety and Metabolism, Astra Zeneca

Mouse Population-Based Approaches to Understand and Predict Adverse Drug Reactions

Merrie Mosedale, PhD, Assistant Director, Institute for Drug Safety Sciences, Research Assistant Professor, The University of North Carolina Eshelman School of Pharmacy

LEVERAGING IN SILICO TOOLS FOR EARLY SAFETY PREDICTIONS

A Case Study in Machine Learning: Integrating Metabolism, Toxicity, and Real-World Evidence

S. Joshua Swamidass, MD, PhD, Assistant Professor, Department of Immunology and Pathology, Division of Laboratory and Genomic Medicine; Faculty Lead, Translational Informatics, Institute for Informatics, Washington University

CASE STUDY: Tapping Modelling and Simulation to Select and Optimize a Lead Biologic Candidate

Renu Singh Dhanikula, PhD, Senior Research investigator, Bristol-Myers Squibb

PANEL DISCUSSION: How Can We Leverage In Vitro and In Silico Tools to Improve Drug Safety?

This panel will bring together speakers and 2-3 technical experts from leading technology and service companies to discuss improvements and limitations in assays, platforms, and data analysis tools available for drug safety assessments.

Moderator: S. Joshua Swamidass, MD, PhD, Assistant Professor, Department of Immunology and Pathology, Division of Laboratory and Genomic Medicine; Faculty Lead, Translational Informatics, Institute for Informatics, Washington University


For more details on the conference, please contact:
Tanuja Koppal, PhD
Conference Producer
Cambridge Healthtech Institute
Email: tkoppal@healthtech.com

For partnering and sponsorship information, please contact:


Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com